SynthesisEuropean journal of clinical pharmacology2024

Effect of subcutaneous vs. intravenous tocilizumab in patients with severe COVID-19: a systematic review.

Yun Li et al.PubMed ↗Publisher ↗

No numbers read from the abstract.